Protective effects of liraglutide on myocardium of AMI patients with the treatment of PCI

doi:10.12092/j.issn.1009-2501.2018.02.013

Abstract

Abstract:

AIM: To investigate the protective effects of liraglutide on myocardium in acute myocardial infarction (AMI) patients treated with percutaneous coronary intervention (PCI). METHODS: One hundred and ten cases of patients diagnosed as AMI, complicated with stress hyperglycemia and treated with PCI were divided into two groups, 55 cases each. Besides standard treatments, observation group was treated with liraglutide while control group was treated with insulin. Factors including creatine phosphokinase (CK), creatine kinase isoenzymes (CKMB), serum cardiac troponin T (cTnT), high-sensitivity C-reactive protein (hs-CRP), nitrogen terminal pro-brain natriuretic peptide (NT-pro-BNP), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and myocardium perfusion defect score were tested before and after treatment between the two groups to compare the efficacy of the two therapeutics. RESULTS:After the surgery, CK, CKMB, cTnT and hs-CRP significantly increased (P<0.05) while NT-pro-BNP decreased significantly (P<0.05) in both groups, and the 48 h peak values of these factors in observation group were significantly lower than those in the control group (t=5.188, 7.081, 2.180, 5.091, 4.748, P<0.05). Compared within groups, the myocardial perfusion defect score at day 30 decreased as compared with day 7 both in the control group (significantly, t=7.963, P<0.05) and in the observation group (not obviously, P>0.05). Compared between the groups, the index in the observation group were lower than that in the control group both at day 7 (significantly, t=6.235, P<0.05) and day 30 (not obviously, P>0.05). LVEF, LVEDD at day 30 increased compared with the indexes at day 7 in both groups, and the differences in the control group were significant (t=6.235, P<0.05). Comparison within the groups showed significant difference between the 30 d LVEF (t=2.032, P<0.05), while other differences were not significant (P>0.05). CONCLUSION: Liraglutide exhibits protective effects on myocardium of AMI patients treated with PCI.

Key words: AMI, liraglutide, PCI, myocardial perfusion defect

CLC Number:

R541

WEI Yuqiang. Protective effects of liraglutide on myocardium of AMI patients with the treatment of PCI[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 184-188.

References

［1］Lnborg J, Vejlstrup N, Kelbak H, et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study［J］. Diabetes, 2014, 63(7): 2474-2485.
［2］Mapanga RF, Essop MF. The damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways［J］. Am J Physiol Heart Circul Physiol, 2016, 310(2): H153-173.
［3］Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems［J］. Diabetes Obes Metab, 2014, 16(8): 673-688.
［4］中华医学会心血管病学分会. 急性ST段抬高型心肌梗死诊断和治疗指南［J］. 中华心血管病杂志, 2010, 38(8): 675-690.
［5］买泓, 宁靓, 赵刚. 静脉溶栓与PCI对急性心肌梗死的疗效对比［J］. 重庆医学, 2014, 8(9): 1133-1135.
［6］史云桃, 蒋廷波. 急性ST段抬高心肌梗死患者合并心力衰竭的危险因素分析［J］. 中华老年心脑血管病杂志, 2014, 16(2): 151-154.
［7］夏梅华, 鲍希静, 李萍, 等. 通心络胶囊联合替罗非班对急性心肌梗死PCI术后患者血栓再形成和炎症因子影响的研究［J］. 中医药导报, 2016, 13(5): 92-94.
［8］樊宗成. 急性心肌梗死伴随应激性高血糖患者冠状动脉造影及临床分析［J］. 中国动脉硬化杂志, 2014, 22(4): 404-406.
［9］高淑娟, 王艾英, 张一兵. 应激性高血糖对非糖尿病急性心肌梗死预后的影响［J］. 中国煤炭工业医学杂志, 2016, 19(11): 1541-1544.
［10］陈敏, 吕莉, 孙晓兰, 等. 心肌酶和红细胞形态学参数与心肌梗死的相关性研究［J］. 现代生物医学进展, 2016, 16(12): 2339-2341.
［11］马宏, 王利青, 尤兆雄. NT-proBNP下降率与急性心肌梗死患者预后的研究［J］. 中国循证心血管医学杂志, 2015, 12(1): 47-48.
［12］陈韦任, 陈韵岱. 利拉鲁肽对急诊行经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者心功能的影响［J］. 中华内科杂志, 2016, 55(4): 327.
［13］朱恩波, 赵光贤, 成宪武. PCI术前后GLP-1受体激动剂治疗对ST段抬高心肌梗死心肌保护作用［J］. 中国心血管病研究, 2014, 12(12): 1133-1135.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[3]	XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu. Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
[4]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[5]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[6]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[7]	QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.
[8]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[9]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[10]	TAO Yanyan, TANG Yajie, WANG Lili, WANG Fangli, LU Guoyu, FAN Fangtian. Clinical characteristics of anticoagulant rodenticide poisoning in northern Anhui analysis of the effect of the vitamin K1 medication regimen on the efficacy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1263-1268.
[11]	LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun. Research progress on the relationship between pediatric epilepsy and vitamin D [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
[12]	ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167.
[13]	SU Yang, ZHOU Feng, DING Jinlei. Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
[14]	WANG Xin, SUN Heliang, ZHANG Qingwei, LIU Cunming, WANG Zhongyun, YANG Chun. Postoperative analgesic effect of low-dose esketamine in patients with thoracoscopic lobectomy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 998-1003.
[15]	DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua. Study on the treatment of thin endometrium with growth hormone and vitamin E [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.